|
1
|
Veronesi U, De Palo G, Marubini E, Costa
A, Formelli F, Mariani L, Decensi A, Camerini T, Del Turco MR, Di
Mauro MG, et al: Randomized trial of fenretinide to prevent second
breast malignancy in women with early breast cancer. J Natl Cancer
Inst. 91:1847–1856. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Veronesi U, Mariani L, Decensi A, Formelli
F, Camerini T, Miceli R, Di Mauro MG, Costa A, Marubini E, Sporn
MB, et al: Fifteen-year results of a randomized phase III trial of
fenretinide to prevent second breast cancer. Ann Oncol.
17:1065–1071. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lazzeroni M and DeCensi A: Breast cancer
prevention by anti-hormones and other drugs: Where do we stand?
Hematol Oncol Clin North Am. 27:657–672. vii2013. View Article : Google Scholar
|
|
4
|
Garattini E, Bolis M, Garattini SK,
Fratelli M, Centritto F, Paroni G, Gianni’ M, Zanetti A, Pagani A,
Fisher JN, et al: Retinoids and breast cancer: From basic studies
to the clinic and back again. Cancer Treat Rev. 40:739–749. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chiesa MD, Passalacqua R, Michiara M,
Franciosi V, Di Costanzo F, Bisagni G, Camisa R, Buti S, Tomasello
G and Cocconi G; Italian Oncology Group for Clinical Research.
Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus
Interferon alpha-2a as first-line endocrine treatments in advanced
breast cancer: Updated results of a phase II, prospective,
randomised multicentre trial. Acta Biomed. 78:204–209. 2007.
|
|
6
|
Decensi A, Robertson C, Guerrieri-Gonzaga
A, Serrano D, Cazzaniga M, Mora S, Gulisano M, Johansson H,
Galimberti V, Cassano E, et al: Randomized double-blind 2 × 2 trial
of low-dose tamoxifen and fenretinide for breast cancer prevention
in high-risk premenopausal women. J Clin Oncol. 27:3749–3756. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bryan M, Pulte ED, Toomey KC, Pliner L,
Pavlick AC, Saunders T and Wieder R: A pilot phase II trial of
all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in
patients with recurrent or metastatic breast cancer. Invest New
Drugs. 29:1482–1487. 2011. View Article : Google Scholar
|
|
8
|
Chambon P: A decade of molecular biology
of retinoic acid receptors. FASEB J. 10:940–954. 1996.PubMed/NCBI
|
|
9
|
Tang XH and Gudas LJ: Retinoids, retinoic
acid receptors, and cancer. Annu Rev Pathol. 6:345–364. 2011.
View Article : Google Scholar
|
|
10
|
Wang Q, Lee D, Sysounthone V, Chandraratna
RAS, Christakos S, Korah R and Wieder R: 1,25-dihydroxyvitamin D3
and retonic acid analogues induce differentiation in breast cancer
cells with function- and cell-specific additive effects. Breast
Cancer Res Treat. 67:157–168. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Christov KT, Shilkaitis AL, Kim ES, Steele
VE and Lubet RA: Chemopreventive agents induce a senescence-like
phenotype in rat mammary tumours. Eur J Cancer. 39:230–239. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shilkaitis A, Green A, Christov K,
Shilkaitis A, Punj V and Steele VE: DHEA inhibits the progression
phase of mammary carcinogenesis by inducing cellular senescence via
a p16 dependent but p53 independent mechanism. Breast Cancer Res.
7:132–140. 2005. View
Article : Google Scholar
|
|
13
|
Christov K, Grubbs CJ, Shilkaitis A,
Juliana MM and Lubet RA: Short-term modulation of cell
proliferation and apoptosis and preventive/therapeutic efficacy of
various agents in a mammary cancer model. Clin Cancer Res.
13:5488–5496. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shilkaitis A, Bratescu L, Green A, Yamada
T and Christov K: Bexarotene induces cellular senescence in
MMTV-Neu mouse model of mammary carcinogenesis. Cancer Prev Res
(Phila). 6:299–308. 2013. View Article : Google Scholar
|
|
15
|
Sugrue MM, Shin DY, Lee SW and Aaronson
SA: Wild-type p53 triggers a rapid senescence program in human
tumor cells lacking functional p53. Proc Natl Acad Sci USA.
94:9648–9653. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chang BD, Xuan Y, Broude EV, Zhu H, Schott
B, Fang J and Roninson IB: Role of p53 and p21waf1/cip1
in senescence-like terminal proliferation arrest induced in human
tumor cells by chemotherapeutic drugs. Oncogene. 18:4808–4818.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chang BD, Broude EV, Dokmanovic M, Zhu H,
Ruth A, Xuan Y, Kandel ES, Lausch E, Christov K and Roninson IB: A
senescence-like phenotype distinguishes tumor cells that undergo
terminal proliferation arrest after exposure to anticancer agents.
Cancer Res. 59:3761–3767. 1999.PubMed/NCBI
|
|
18
|
Campisi J: Senescent cells, tumor
suppression, and organismal aging: Good citizens, bad neighbors.
Cell. 120:513–522. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bartkova J, Rezaei N, Liontos M,
Karakaidos P, Kletsas D, Issaeva N, Vassiliou LV, Kolettas E,
Niforou K, Zoumpourlis VC, et al: Oncogene-induced senescence is
part of the tumorigenesis barrier imposed by DNA damage
checkpoints. Nature. 444:633–637. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Collado M and Serrano M: The power and the
promise of oncogene-induced senescence markers. Nat Rev Cancer.
6:472–476. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sarkisian CJ, Keister BA, Stairs DB, Boxer
RB, Moody SE and Chodosh LA: Dose-dependent oncogene-induced
senescence in vivo and its evasion during mammary tumorigenesis.
Nat Cell Biol. 9:493–505. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kuilman T and Peeper DS:
Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev
Cancer. 9:81–94. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Capparelli C, Chiavarina B,
Whitaker-Menezes D, Pestell TG, Pestell RG, Hulit J, Andò S, Howell
A, Martinez-Outschoorn UE, Sotgia F, et al: CDK inhibitors
(p16/p19/p21) induce senescence and autophagy in cancer-associated
fibroblasts, ‘fueling’ tumor growth via paracrine interactions,
without an increase in neoangiogenesis. Cell Cycle. 11:3599–3610.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mumcuoglu M, Bagislar S, Yuzugullu H,
Alotaibi H, Senturk S, Telkoparan P, Gur-Dedeoglu B, Cingoz B,
Bozkurt B, Tazebay UH, et al: The ability to generate senescent
progeny as a mechanism underlying breast cancer cell heterogeneity.
PLoS One. 5:e112882010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dokmanovic M, Chang BD, Fang J and
Roninson IB: Retinoid-induced growth arrest of breast carcinoma
cells involves co-activation of multiple growth-inhibitory genes.
Cancer Biol Ther. 1:24–27. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tanaka T, Rodríguez de la Concepción ML
and De Luca LM: Involvement of all-trans-retinoic acid in the
breakdown of retinoic acid receptors alpha and gamma through
proteasomes in MCF-7 human breast cancer cells. Biochem Pharmacol.
61:1347–1355. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brown NE, Jeselsohn R, Bihani T, Hu MG,
Foltopoulou P, Kuperwasser C and Hinds PW: Cyclin D1 activity
regulates autophagy and senescence in the mammary epithelium.
Cancer Res. 72:6477–6489. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Angelini PD, Zacarias Fluck MF, Pedersen
K, Parra-Palau JL, Guiu M, Bernadó Morales C, Vicario R,
Luque-García A, Navalpotro NP, Giralt J, et al: Constitutive HER2
signaling promotes breast cancer metastasis through cellular
senescence. Cancer Res. 73:450–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim HT, Kong G, Denardo D, Li Y, Uray I,
Pal S, Mohsin S, Hilsenbeck SG, Bissonnette R, Lamph WW, et al:
Identification of biomarkers modulated by the rexinoid LGD1069
(bexarotene) in human breast cells using oligonucleotide arrays.
Cancer Res. 66:12009–12018. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bruno S, Ghiotto F, Tenca C, Mazzarello
AN, Bono M, Luzzi P, Casciaro S, Recchia A, Decensi A, Morabito F,
et al: N-(4-hydroxyphenyl)retinamide promotes apoptosis of resting
and proliferating B-cell chronic lymphocytic leukemia cells and
potentiates fludarabine and ABT-737 cytotoxicity. Leukemia.
26:2260–2268. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wainwright LJ, Lasorella A and Iavarone A:
Distinct mechanisms of cell cycle arrest control the decision
between differentiation and senescence in human neuroblastoma
cells. Proc Natl Acad Sci USA. 98:9396–9400. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Paroni G, Fratelli M, Gardini G, Bassano
C, Flora M, Zanetti A, Guarnaccia V, Ubezio P, Centritto F, Terao
M, et al: Synergistic antitumor activity of lapatinib and retinoids
on a novel subtype of breast cancer with coamplification of ERBB2
and RARA. Oncogene. 31:3431–3443. 2012. View Article : Google Scholar
|
|
33
|
Han J, Hendzel MJ and Allalunis-Turner J:
Notch signaling as a therapeutic target for breast cancer
treatment? Breast Cancer Res. 13:210–221. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Deisenroth C, Itahana Y, Tollini L, Jin A
and Zhang Y: p53-Inducible DHRS3 is an endoplasmic reticulum
protein associated with lipid droplet accumulation. J Biol Chem.
286:28343–28356. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Morales M, Arenas EJ, Urosevic J, Guiu M,
Fernández E, Planet E, Fenwick RB, Fernández-Ruiz S, Salvatella X,
Reverter D, et al: RARRES3 suppresses breast cancer lung metastasis
by regulating adhesion and differentiation. EMBO Mol Med.
6:865–881. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Azouz A, Wu YL, Hillion J, Tarkanyi I,
Karniguian A, Aradi J, Lanotte M, Chen GQ, Chehna M and
Ségal-Bendirdjian E: Epigenetic plasticity of hTERT gene promoter
determines retinoid capacity to repress telomerase in
maturation-resistant acute promyelocytic leukemia cells. Leukemia.
24:613–622. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jin RU and Mills JC: RAB26 coordinates
lysosome traffic and mitochondrial localization. J Cell Sci.
127:1018–1032. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Uray IP, Shen Q, Seo HS, Kim H, Lamph WW,
Bissonnette RP and Brown PH: Rexinoid-induced expression of IGFBP-6
requires RARbeta-dependent permissive cooperation of retinoid
receptors and AP-1. J Biol Chem. 284:345–353. 2009. View Article : Google Scholar :
|
|
39
|
Widschwendter M, Berger J, Daxenbichler G,
Müller-Holzner E, Widschwendter A, Mayr A, Marth C and Zeimet AG:
Loss of retinoic acid receptor beta expression in breast cancer and
morphologically normal adjacent tissue but not in the normal breast
tissue distant from the cancer. Cancer Res. 57:4158–4161.
1997.PubMed/NCBI
|
|
40
|
Liu Y, Lee MO, Wang HG, Li Y, Hashimoto Y,
Klaus M, Reed JC and Zhang X: Retinoic acid receptor beta mediates
the growth-inhibitory effect of retinoic acid by promoting
apoptosis in human breast cancer cells. Mol Cell Biol.
16:1138–1149. 1996.PubMed/NCBI
|
|
41
|
Pappas JJ, Toulouse A, Basik M, Levesque L
and Bradley WEC: Knock-down of RARβ2 identifies a dual role of
cancer, genes. Chromosom Cancer. 50:700–714. 1911. View Article : Google Scholar
|
|
42
|
Peng X, Maruo T, Cao Y, Punj V, Mehta R,
Das Gupta TK and Christov K: A novel RARbeta isoform directed by a
distinct promoter P3 and mediated by retinoic acid in breast cancer
cells. Cancer Res. 64:8911–8918. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Christov K: The novel RARbeta isoform (β5)
is a potential target of retinoids in breast cancer. Curr Cancer
Drug Targets. 9:142–147. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bosch A, Bertran SP, Lu Y, Garcia A, Jones
AM, Dawson MI and Farias EF: Reversal by RARα agonist Am580 of
c-Myc-induced imbalance in RARα/RARγ expression during MMTV-Myc
tumorigenesis. Breast Cancer Res. 14:R1212012. View Article : Google Scholar
|
|
45
|
Chen Y, Dokmanovic M, Stein WD, Ardecky RJ
and Roninson IB: Agonist and antagonist of retinoic acid receptors
cause similar changes in gene expression and induce senescence-like
growth arrest in MCF-7 breast carcinoma cells. Cancer Res.
66:8749–8761. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sirchia SM, Ferguson AT, Sironi E,
Subramanyan S, Orlandi R, Sukumar S and Sacchi N: Evidence of
epigenetic changes affecting the chromatin state of the retinoic
acid receptor beta2 promoter in breast cancer cells. Oncogene.
19:1556–1563. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dimri GP, Lee X, Basile G, Acosta M, Scott
G, Roskelley C, Medrano EE, Linskens M, Rubelj I and Pereira-Smith
O: A biomarker that identifies senescent human cells in culture and
in aging skin in vivo. Proc Natl Acad Sci USA. 92:9363–9367. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bednarek A, Shilkaitis A, Green A, Lubet
R, Kelloff G, Christov K and Aldaz CM: Suppression of cell
proliferation and telomerase activity in
4-(hydroxyphenyl)retinamide-treated mammary tumors. Carcinogenesis.
20:879–883. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Feldser DM and Greider CW: Short telomeres
limit tumor progression in vivo by inducing senescence. Cancer
Cell. 11:461–469. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Collado M, Gil J, Efeyan A, Guerra C,
Schuhmacher AJ, Barradas M, Benguría A, Zaballos A, Flores JM,
Barbacid M, et al: Tumour biology: Senescence in premalignant
tumours. Nature. 436:6422005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Michaloglou C, Vredeveld LC, Soengas MS,
Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi
WJ and Peeper DS: BRAFE600-associated senescence-like cell cycle
arrest of human naevi. Nature. 436:720–724. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
te Poele RH, Okorokov AL, Jardine L,
Cummings J and Joel SP: DNA damage is able to induce senescence in
tumor cells in vitro and in vivo. Cancer Res. 62:1876–1883.
2002.PubMed/NCBI
|
|
53
|
Green DR and Walczak H: Apoptosis therapy:
Driving cancers down the road to ruin. Nat Med. 19:131–133. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Collado M and Serrano M: Senescence in
tumours: Evidence from mice and humans. Nat Rev Cancer. 10:51–57.
2010. View Article : Google Scholar
|
|
55
|
Nardella C, Clohessy JG, Alimonti A and
Pandolfi PP: Pro-senescence therapy for cancer treatment. Nat Rev
Cancer. 11:503–511. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Brown PH, Subbaramaiah K, Salmon AP, Baker
R, Newman RA, Yang P, Zhou XK, Bissonnette RP, Dannenberg AJ and
Howe LR: Combination chemoprevention of HER2/Neu-induced breast
cancer using COX-2 inhibitor and an RXR-selective retinoid. Cancer
Prev Res (Phila). 1:208–214. 2008. View Article : Google Scholar
|
